Tremendous advancements have been made in diagnosis and treatment with the recent FDA approval of a targeted therapy for metastatic bladder cancer with FGFR3 or FGFR2 genetic alterations, two combination immunotherapy-targeted therapies as first-line treatment for advanced RCC, as well as advances in diagnostics and immunotherapy research for prostate cancer
Take advantage of this highly anticipated event and immerse yourself in the evolving landscape of urological cancer care.
For more information and to register, click here. Space is limited!
Prague, Czech Republic | 23rd to 25th January 2020
More information here.
The SIU Congress App is available for download via App Store, Google Play, the Windows Phone Store and BlackBerry World